A genetics-first alternative from PlexusDx PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols, sold as Semaglutide Injection ($189/month), Semaglutide Oral, Tirzepatide Injection ($289/month), and Tirzepatide Oral
However, the high drug costs of first-line SGLT2i and GLP-1RAs render them cost-ineffective in the US population
They are essential
Clinicians should monitor patients for potential adverse effects including pancreatitis (severe, persistent abdominal pain), gallbladder disease (right upper quadrant pain), diabetic retinopathy complications (especially with rapid glucose improvement), acute kidney injury with dehydration, and hypoglycemia when combined with insulin or sulfonylureas
If you need weight loss treatment now, FDA-approved options like semaglutide and tirzepatide are available today with years of real-world safety data
How Common Are Adverse Events From Compounded GLP-1s